Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
US Department of Justice
McKesson
Deloitte
Colorcon
Chinese Patent Office
Medtronic
Harvard Business School
Cerilliant
Mallinckrodt

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,034,370

« Back to Dashboard

Which drugs does patent 9,034,370 protect, and when does it expire?

Patent 9,034,370 protects DAYTRANA and is included in one NDA.

This patent has one patent family member in one country.
Summary for Patent: 9,034,370
Title:Device for transdermal administration of drugs including acrylic polymers
Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Inventor(s): Kanios; David (Palmetto Bay, FL)
Assignee: NOVEN PHARMACEUTICALS, INC. (Miami, FL)
Application Number:14/133,900
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use; Device;

Drugs Protected by US Patent 9,034,370

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,034,370

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,632,802 Device for transdermal administration of drugs including acrylic polymers ➤ Subscribe
8,916,191 Device for transdermal administration of drugs including acrylic polymers ➤ Subscribe
9,668,981 Device for transdermal administration of drugs including acrylic based polymers ➤ Subscribe
9,333,263 Device for transdermal administration of drugs including acrylic based polymers ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
US Army
Boehringer Ingelheim
Medtronic
Cipla
US Department of Justice
Dow
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot